Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorRavegnini, Gloria
dc.contributor.authorNannini, Margherita
dc.contributor.authorIndio, Valentina
dc.contributor.authorSerrano Garcia, César
dc.contributor.authorGorini, Francesca
dc.contributor.authorAstolf, Annalisa
dc.date.accessioned2022-11-28T11:02:05Z
dc.date.available2022-11-28T11:02:05Z
dc.date.issued2022-10-14
dc.identifier.citationRavegnini G, Nannini M, Indio V, Serrano C, Gorini F, Astolfi A, et al. miRNA Expression May Have Implications for Immunotherapy in PDGFRA Mutant GISTs. Int J Mol Sci. 2022 Oct 14;23(20):12248.
dc.identifier.issn1422-0067
dc.identifier.urihttps://hdl.handle.net/11351/8537
dc.descriptionGastrointestinal stromal tumors; MiRNAs; MicroRNAs
dc.description.abstractGastrointestinal stromal tumors (GISTs) harboring mutations in the PDGFRA gene occur in only about 5–7% of patients. The most common PDGFRA mutation is exon 18 D842V, which is correlated with specific clinico-pathological features compared to the other PDGFRA mutated GISTs. Herein, we present a miRNA expression profile comparison of PDGFRA D842V mutant GISTs and PDGFRA with mutations other than D842V (non-D842V). miRNA expression profiling was carried out on 10 patients using a TLDA miRNA array. Then, miRNA expression was followed by bioinformatic analysis aimed at evaluating differential expression, pathway enrichment, and miRNA-mRNA networks. We highlighted 24 differentially expressed miRNAs between D842V and non-D842V GIST patients. Pathway enrichment analysis showed that deregulated miRNAs targeted genes that are mainly involved in the immune response pathways. The miRNA-mRNA networks highlighted a signature of miRNAs/mRNA that could explain the indolent behavior of the D842V mutated GIST. The results highlighted a different miRNA fingerprint in PDGFRA D842V GISTs compared to non-D842Vmutated patients, which could explain the different biological behavior of this GIST subset.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesInternational Journal of Molecular Sciences;23(20)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectAparell digestiu - Càncer - Aspectes genètics
dc.subjectAnomalies cromosòmiques
dc.subjectAparell digestiu - Càncer - Immunoteràpia
dc.subject.meshGastrointestinal Stromal Tumors
dc.subject.meshImmunotherapy
dc.subject.meshMutation
dc.titlemiRNA Expression May Have Implications for Immunotherapy in PDGFRA Mutant GISTs
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/ijms232012248
dc.subject.decstumores del estroma gastrointestinal
dc.subject.decsinmunoterapia
dc.subject.decsmutación
dc.relation.publishversionhttps://doi.org/10.3390/ijms232012248
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Ravegnini G, Gorini F] Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy. [Nannini M] Department of Specialized, Experimental and Diagnostic Medicine, Sant’Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. Division of Oncology, IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy. [Indio V] Department of Veterinary Medical Sciences, University of Bologna, Ozzano, Italy. [Serrano C] Sarcoma Translational Research Laboratory, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Astolfi A] Department of Specialized, Experimental and Diagnostic Medicine, Sant’Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
dc.identifier.pmid36293105
dc.identifier.wos000875423400001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record